Why Arvinas, Inc.’s (ARVN) Stock Is Up 6.00%
As of Wednesday, September 30, Arvinas, Inc.’s ARVN share price has surged by 6.00%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing clinical development programs , including ARV-102, a leucine-rich repeat kinase 2 (LRRK2) protein for the treatment of neurodegenerative diseases, such as Parkinson's disease and progressive supranuclear palsy; ARV-806, a Kirsten rat sarcoma, G12D protein for the treatment of cancers with the G12D mutation, comprising pancreatic, colorectal, and non-small cell lung cancer; ARV-393, a B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL); ARV-027, a polyglutamine-expanded androgen receptor in skeletal muscle; and vepdegestrant, an estrogen receptor for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. In addition, the company develops Bavdegalutamide (ARV-110) and Luxdegalutamide (ARV-766), investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer. It has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Commentary & Analysis
Why Arvinas, Inc.’s (ARVN) Stock Is Down 5.11%
As of Thursday, September 24, Arvinas, Inc.’s ARVN share price has dipped by 5.11%, which has investors questioning if this is right time to buy.Michael Rose
Why Arvinas, Inc.’s (ARVN) Stock Is Up 7.26%
As of Friday, August 21, Arvinas, Inc.’s ARVN share price has surged by 7.26%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Is Arvinas, Inc. (ARVN) Overvalued?
We dive into why Arvinas, Inc. (ARVN) could be considered overvalued on 2026-08-07, based on AAII’s Value Score and Grade.Jenna Brashear
Why Arvinas, Inc.’s (ARVN) Stock Is Down 7.61%
As of Wednesday, August 05, Arvinas, Inc.’s ARVN share price has dipped by 7.61%, which has investors questioning if this is right time to buy.Michael Rose
Financial Summary
| Share Statistics | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $505.8 | $560.7 | 38% |
|
| Shares Out (Mil) | 65.7 | 42.3 | 54% |
|
| Institutional Ownership | 96.8% | 84.3% | 71% |
|
| Float (Mil) | 56.8 | 45.7 | 50% |
|
| Beta | 1.76 | 0.72 | 88% |
|
| Avg Daily Volume (000s) | 840 | 392 | 65% |
|
| Price Change (52-week) |
(9.3%) | 60.8% | 44% |
|
| Growth | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 58.9% | 5.7% | 97% |
|
| Net Income (5yr) | 7.5% | (1.5%) | 51% |
|
| EPS (5yr) | 17.7% | 15.1% | 64 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (47.2%) | (15.1%) | 8% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 12 | 12 | 12 | |
| Current EPS | ($0.948) | ($0.137) | ($3.232) | |
| Month Ago EPS | ($0.937) | ($0.099) | ($3.079) | |
| # Rev Up | 1 | 0 | 0 | |
| # Rev Down | 1 | 1 | 2 | |
| Three Months Ago EPS | ($0.830) | ($2.864) | ($3.449) | |
| Year/Year Chg | (136.7%) | (88.0%) | 136.1% | |
| Financials | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $317 | $326 | 36% |
|
| Net Income (TTM) (Mil) | $9 | ($11) | 45% |
|
| EPS (TTM) | $0.139 | ($0.700) | 44% |
|
| Operating Cash Flow (TTM) (Mil) | ($207) | ($7) | 4% |
|
| Net Cash Flow (TTM) (Mil) | ($21) | $6 | 26% |
|
| Long-Term Debt (Q1) (Mil) | $6 | $6 | 26% |
|
| Enterprise Value (Q1) (Mil) | ($18) | $493 | 1% |
|
| Valuation | ARVN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.90 | 2.34 | 20% |
|
| P/E | 57.7 | 17.3 | 87% |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | 3.3 | 1.1 | 81% |
|
| Ratios | ARVN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 97.2% | 69.4% | 96% |
|
| Net Margin | 2.9% | 2.5% | 41% |
|
| ROA | 1.2% | (22.4%) | 48% |
|
| ROE | 1.6% | (23.8%) | 37% |
|
| Liabilities to Assets | 16.7% | 32.6% | 11% |
|
| F-Score | 6 | 3 | 67% |
|
Passing Stock Screens
As of 9/30/2026, from a list of 60 stock screening strategies,
FACTOR STRATEGY
Price-to-Sales Screen
Factors: Value, Growth
Research indicates that using price-to-sales ratios may lead to better investment results than price-to-book-value ratios or price-earnings ratios.
| Performance Since Inception: | 13.0% |
| +/- S&P 500: | +5.5 |
FACTOR STRATEGY
Est Rev: Lowest 30 Down
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 3.0% |
| +/- S&P 500: | -4.5 |
FACTOR STRATEGY
Est Rev: Down 5% Screen
Factors: Earnings Estimates
Introduction to the use of earnings estimates.
| Performance Since Inception: | 2.3% |
| +/- S&P 500: | -5.2 |
